Merus N.V. (MRUS)
- Previous Close
44.52 - Open
45.06 - Bid 45.76 x 100
- Ask 45.93 x 200
- Day's Range
44.74 - 46.51 - 52 Week Range
19.81 - 52.03 - Volume
826,115 - Avg. Volume
635,793 - Market Cap (intraday)
2.691B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.73 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
60.92
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
www.merus.nlRecent News: MRUS
Performance Overview: MRUS
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRUS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRUS
Valuation Measures
Market Cap
2.69B
Enterprise Value
2.36B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
65.24
Price/Book (mrq)
7.70
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.89%
Return on Equity (ttm)
-52.79%
Revenue (ttm)
38.34M
Net Income Avi to Common (ttm)
-149.65M
Diluted EPS (ttm)
-2.73
Balance Sheet and Cash Flow
Total Cash (mrq)
337.5M
Total Debt/Equity (mrq)
3.30%
Levered Free Cash Flow (ttm)
-128.29M
Research Analysis: MRUS
Company Insights: MRUS
MRUS does not have Company Insights